ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMFrais de vente, généraux et administratifs211.4 M258.4 M249.5 M221.5 M233 M244.7 M948.7 MRecherche et développement27.8 M26.7 M22 M24.9 M21.8 M24.6 M93.3 MRésultat d'exploitation114.2 M46.9 M45.4 M72.6 M-1.29 B-372.3 M-1.54 BTotal des produits hors exploitation600 K400 K-2.6 M-9.6 M-1.4 M6 M-7.6 MCharges d'intérêts, nettes des intérêts capitalisés8 M2.3 M2.3 M2.4 M2.5 M2.3 M9.5 MRésultat hors exploitation, hors charges d'intérêts-8 M-2.3 M-2.3 M-2.4 M-2.5 M-2.3 M-9.5 MRevenus/dépenses exceptionnels600 K400 K-2.6 M-9.6 M-1.4 M6 M-7.6 MRésultat avant impôts70.1 M8.3 M3.2 M22.4 M-1.33 B-408.5 M-1.71 BPart des actionnaires dans le résultat-300 K-100 K-400 K-200 K-33.6 M100 K-34.1 MImpôts111.6 M8.2 M3.7 M9.7 M82.8 M-18.7 M77.5 MIntérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts———————Résultat net avant activités abandonnées-41.5 M100 K-500 K12.7 M-1.41 B-389.9 M-1.79 BActivités abandonnées-2.9 M-6.5 M-7.9 M-5.2 M-3.5 M-8.7 M-25.3 MRésultat net-44.4 M-6.4 M-8.4 M7.5 M-1.42 B-398.6 M-1.82 BAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires-44.4 M-6.4 M-8.4 M7.5 M-1.42 B-398.6 M-1.82 BBénéfice par action de base (BPA de base)-0.32-0.05-0.060.05-10.23-2.87-13.11Bénéfice par action dilué (BPA dilué)-0.32-0.05-0.060.05-10.23-2.87-13.11Nombre moyen d'actions de base en circulation137.4 M137.7 M138.2 M138.5 M138.5 M138.7 M—Nombre d'actions en circulation après dilution137.4 M137.7 M138.2 M138.9 M138.5 M138.7 M—EBITDA194.5 M126.8 M131.7 M158 M-1.2 B-289 M-1.2 BEBIT114.2 M46.9 M45.4 M72.6 M-1.29 B-372.3 M-1.54 BCoût des ventes752.4 M651.6 M693.4 M666.2 M747.4 M643.7 M2.75 BAutres coûts des ventes———————Amortissements (flux de trésorerie)80.3 M79.9 M86.3 M85.4 M85.9 M83.3 M340.9 M
Perrigo Company plc Ordinary Shares
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.